# JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

> **NCT06954467** · PHASE2 · RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** JS207
- **DRUG:** JS007

## Key facts

- **NCT ID:** NCT06954467
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06954467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06954467, "JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06954467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*